{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:40:34Z","timestamp":1790912434612,"version":"4.1.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T00:00:00Z","timestamp":1655424000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T00:00:00Z","timestamp":1655424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2019-00209"],"award-info":[{"award-number":["2019-00209"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","award":["190043"],"award-info":[{"award-number":["190043"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2022,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>To investigate if anti-androgenic medications 5\u03b1-reductase inhibitors (5-ARIs) decrease the risk of developing oesophageal and gastric tumours, analysed by histological type and anatomical sub-site.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A Swedish population-based cohort study between 2005 and 2018 where men using 5-ARIs were considered exposed. For each exposed participant, ten male age-matched non-users of 5-ARIs (non-exposed) were included. Multivariable Cox regression provided hazard ratios (HR) with 95% confidence intervals (CI) adjusted for age, calendar year, smoking, non-steroidal anti-inflammatory drugs\/aspirin use, and statins use. Further adjustments were made depending on the tumour analysed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The cohort included 191,156 users of 5-ARIs and 1,911,560 non-users. Overall, the use of 5-ARIs was not associated with any statistically significantly reduced risk of oesophageal or cardia adenocarcinoma (adjusted HR 0.92, 95% CI 0.82\u20131.02) or gastric non-cardia adenocarcinoma (adjusted HR 0.90, 95% CI 0.80\u20131.02). However, the use of 5-ARIs indicated a decreased risk of oesophageal or cardia adenocarcinoma among obese or diabetic participants (adjusted HR 0.55, 95% CI 0.39\u20130.80) and a reduced risk of oesophageal squamous cell carcinoma (adjusted HR 0.49, 95% CI 0.37\u20130.65).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Users of 5-ARIs may have a decreased risk of developing oesophageal or cardia adenocarcinoma among those obese or diabetic, and a decreased risk of oesophageal squamous cell carcinoma.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41416-022-01872-w","type":"journal-article","created":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T07:26:00Z","timestamp":1655450760000},"page":"892-897","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Use of anti-androgenic 5\u03b1-reductase inhibitors and risk of oesophageal and gastric cancer by histological type and anatomical sub-site"],"prefix":"10.1038","volume":"127","author":[{"given":"Sirus","family":"Rabbani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giola","family":"Santoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesper","family":"Lagergren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4270-1281","authenticated-orcid":false,"given":"Shao-Hua","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,17]]},"reference":[{"key":"1872_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394\u2013424.","journal-title":"CA Cancer J Clin"},{"key":"1872_CR2","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1016\/S0140-6736(17)31462-9","volume":"390","author":"J Lagergren","year":"2017","unstructured":"Lagergren J, Smyth E, Cunningham D, Lagergren P. Oesophageal cancer. Lancet. 2017;390:2383\u201396.","journal-title":"Lancet."},{"key":"1872_CR3","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1001\/jamaoncol.2018.2706","volume":"4","author":"C Fitzmaurice","year":"2018","unstructured":"Fitzmaurice C, Akinyemiju TF, Al Lami FH, Alam T, Alizadeh-Navaei R, Allen C, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: a systematic analysis for the global burden of disease study. JAMA Oncol. 2018;4:1553\u201368.","journal-title":"JAMA Oncol."},{"key":"1872_CR4","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/S0140-6736(20)31288-5","volume":"396","author":"EC Smyth","year":"2020","unstructured":"Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F. Gastric cancer. Lancet. 2020;396:635\u201348.","journal-title":"Lancet."},{"key":"1872_CR5","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1053\/j.gastro.2017.07.046","volume":"154","author":"HG Coleman","year":"2018","unstructured":"Coleman HG, Xie SH, Lagergren J. The epidemiology of esophageal adenocarcinoma. Gastroenterology. 2018;154:390\u2013405.","journal-title":"Gastroenterology."},{"key":"1872_CR6","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.cgh.2015.10.005","volume":"14","author":"SH Xie","year":"2016","unstructured":"Xie SH, Lagergren J. The male predominance in esophageal adenocarcinoma. Clin Gastroenterol Hepatol. 2016;14:338\u201347.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1872_CR7","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1136\/gut.2008.161331","volume":"58","author":"MH Derakhshan","year":"2009","unstructured":"Derakhshan MH, Liptrot S, Paul J, Brown IL, Morrison D, McColl KE. Oesophageal and gastric intestinal-type adenocarcinomas show the same male predominance due to a 17 year delayed development in females. Gut. 2009;58:16\u201323.","journal-title":"Gut."},{"key":"1872_CR8","doi-asserted-by":"publisher","first-page":"e0190325","DOI":"10.1371\/journal.pone.0190325","volume":"13","author":"JL Petrick","year":"2018","unstructured":"Petrick JL, Falk RT, Hyland PL, Caron P, Pfeiffer RM, Wood SN, et al. Association between circulating levels of sex steroid hormones and esophageal adenocarcinoma in the FINBAR Study. PLoS ONE. 2018;13:e0190325.","journal-title":"PLoS ONE"},{"key":"1872_CR9","doi-asserted-by":"publisher","first-page":"216","DOI":"10.14309\/ajg.0000000000000446","volume":"115","author":"SH Xie","year":"2020","unstructured":"Xie SH, Ness-Jensen E, Rabbani S, Langseth H, Gislefoss RE, Mattsson F, et al. Circulating sex hormone levels and risk of esophageal adenocarcinoma in a prospective study in men. Am J Gastroenterol. 2020;115:216\u201323.","journal-title":"Am J Gastroenterol"},{"key":"1872_CR10","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1093\/jnci\/djy082","volume":"111","author":"JL Petrick","year":"2019","unstructured":"Petrick JL, Hyland PL, Caron P, Falk RT, Pfeiffer RM, Dawsey SM, et al. Associations between prediagnostic concentrations of circulating sex steroid hormones and esophageal\/gastric cardia adenocarcinoma among men. J Natl Cancer Inst. 2019;111:34\u201341.","journal-title":"J Natl Cancer Inst"},{"key":"1872_CR11","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1136\/gutjnl-2014-308124","volume":"64","author":"M Arnold","year":"2015","unstructured":"Arnold M, Soerjomataram I, Ferlay J, Forman D. Global incidence of oesophageal cancer by histological subtype in 2012. Gut. 2015;64:381\u20137.","journal-title":"Gut."},{"key":"1872_CR12","doi-asserted-by":"publisher","first-page":"e033323","DOI":"10.1136\/bmjopen-2019-033323","volume":"10","author":"L Lou","year":"2020","unstructured":"Lou L, Wang L, Zhang Y, Chen G, Lin L, Jin X, et al. Sex difference in incidence of gastric cancer: an international comparative study based on the Global Burden of Disease Study 2017. BMJ Open. 2020;10:e033323.","journal-title":"BMJ Open"},{"key":"1872_CR13","doi-asserted-by":"publisher","first-page":"S109","DOI":"10.5489\/cuaj.1114","volume":"3","author":"L Goldenberg","year":"2009","unstructured":"Goldenberg L, So A, Fleshner N, Rendon R, Drachenberg D, Elhilali M. The role of 5-alpha reductase inhibitors in prostate pathophysiology: Is there an additional advantage to inhibition of type 1 isoenzyme? Can Urol Assoc J. 2009;3:S109\u201314.","journal-title":"Can Urol Assoc J."},{"key":"1872_CR14","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S0090-4295(01)01299-7","volume":"58","author":"WD Steers","year":"2001","unstructured":"Steers WD. 5alpha-reductase activity in the prostate. Urology. 2001;58:17\u201324.","journal-title":"Urology."},{"key":"1872_CR15","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1111\/j.1464-410X.2009.08915.x","volume":"105","author":"SK Hong","year":"2010","unstructured":"Hong SK, Min GE, Ha SB, Doo SH, Kang MY, Park HJ, et al. Effect of the dual 5\u03b1-reductase inhibitor, dutasteride, on serum testosterone and body mass index in men with benign prostatic hyperplasia. BJU Int. 2010;105:970\u20134.","journal-title":"BJU Int"},{"key":"1872_CR16","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/pds.4909","volume":"29","author":"J Busby","year":"2020","unstructured":"Busby J, Karasneh R, Murchie P, McMenamin \u00da, Gadalla SM, Camargo MC, et al. The role of 5\u03b1-reductase inhibitors in gastro-oesophageal cancer risk: a nested case-control study. Pharmacoepidemiol Drug Saf. 2020;29:48\u201356.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1872_CR17","doi-asserted-by":"publisher","first-page":"e023155","DOI":"10.1136\/bmjopen-2018-023155","volume":"9","author":"SH Xie","year":"2019","unstructured":"Xie SH, Santoni G, Mattsson F, Ness-Jensen E, Lagergren J. Cohort profile: the Swedish Prescribed Drugs and Health Cohort (SPREDH). BMJ Open. 2019;9:e023155.","journal-title":"BMJ Open"},{"key":"1872_CR18","unstructured":"Eeg-Olofsson K, Miftaraj M, Svensson A-M, Linder, E, Almskog, I, Franz\u00e9n, S, et al. Nationella Diabetesregistret \u00c5RSRAPPORT 2020 \u00c5RS RESULTAT. V\u00e4stra g\u00f6talandsregionen: Nationella Diabetesregistret (NDR); 2020."},{"key":"1872_CR19","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1111\/j.1365-2265.2012.04432.x","volume":"77","author":"G Sartorius","year":"2012","unstructured":"Sartorius G, Spasevska S, Idan A, Turner L, Forbes E, Zamojska A, et al. Serum testosterone, dihydrotestosterone and estradiol concentrations in older men self-reporting very good health: the healthy man study. Clin Endocrinol. 2012;77:755\u201363.","journal-title":"Clin Endocrinol"},{"key":"1872_CR20","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1002\/pros.23285","volume":"77","author":"Z Klaassen","year":"2017","unstructured":"Klaassen Z, Howard LE, Moreira DM, Andriole GL Jr, Terris MK, Freedland SJ. Association of obesity-related hemodilution of prostate-specific antigen, dihydrotestosterone, and testosterone. Prostate. 2017;77:466\u201370.","journal-title":"Prostate"},{"key":"1872_CR21","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1210\/jc.2006-2203","volume":"92","author":"JK Amory","year":"2007","unstructured":"Amory JK, Wang C, Swerdloff RS, Anawalt BD, Matsumoto AM, Bremner WJ, et al. The effect of 5\u03b1-reductase inhibition with dutasteride and finasteride on semen parameters and serum hormones in healthy men. J Clin Endocrinol Metab. 2007;92:1659\u201365.","journal-title":"J Clin Endocrinol Metab"},{"key":"1872_CR22","first-page":"3107","volume":"21","author":"T Tihan","year":"2001","unstructured":"Tihan T, Harmon JW, Wan X, Younes Z, Nass P, Duncan KL, et al. Evidence of androgen receptor expression in squamous and adenocarcinoma of the esophagus. Anticancer Res. 2001;21:3107\u201314.","journal-title":"Anticancer Res"},{"key":"1872_CR23","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1111\/j.1442-2050.2007.00767.x","volume":"21","author":"R Kalayarasan","year":"2008","unstructured":"Kalayarasan R, Ananthakrishnan N, Kate V, Basu D. Estrogen and progesterone receptors in esophageal carcinoma. Dis Esophagus. 2008;21:298\u2013303.","journal-title":"Dis Esophagus"},{"key":"1872_CR24","doi-asserted-by":"publisher","first-page":"5859","DOI":"10.1007\/s13277-015-3257-x","volume":"36","author":"Y Zhang","year":"2015","unstructured":"Zhang Y, Pan T, Zhong X, Cheng C. Androgen receptor promotes esophageal cancer cell migration and proliferation via matrix metalloproteinase 2. Tumour Biol. 2015;36:5859\u201364.","journal-title":"Tumour Biol"},{"key":"1872_CR25","first-page":"4134","volume":"47","author":"H Matsuoka","year":"1987","unstructured":"Matsuoka H, Sugimachi K, Ueo H, Kuwano H, Nakano S, Nakayama M. Sex hormone response of a newly established squamous cell line derived from clinical esophageal carcinoma. Cancer Res. 1987;47:4134\u201340.","journal-title":"Cancer Res"},{"key":"1872_CR26","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1002\/cncr.24880","volume":"116","author":"ND Freedman","year":"2010","unstructured":"Freedman ND, Lacey JV Jr, Hollenbeck AR, Leitzmann MF, Schatzkin A, Abnet CC. The association of menstrual and reproductive factors with upper gastrointestinal tract cancers in the NIH-AARP cohort. Cancer. 2010;116:1572\u201381.","journal-title":"Cancer."},{"key":"1872_CR27","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1158\/1940-6207.CAPR-10-0389","volume":"4","author":"C Bodelon","year":"2011","unstructured":"Bodelon C, Anderson GL, Rossing MA, Chlebowski RT, Ochs-Balcom HM, Vaughan TL. Hormonal factors and risks of esophageal squamous cell carcinoma and adenocarcinoma in postmenopausal women. Cancer Prev Res. 2011;4:840.","journal-title":"Cancer Prev Res."},{"key":"1872_CR28","first-page":"1953","volume":"12","author":"H Yu","year":"2011","unstructured":"Yu H, Liu G, Zhao P, Zhu L. Hormonal and reproductive factors and risk of esophageal cancer in Chinese postmenopausal women: a case-control study. Asian Pac J Cancer Prev. 2011;12:1953\u20136.","journal-title":"Asian Pac J Cancer Prev"},{"key":"1872_CR29","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1054\/bjoc.2001.1898","volume":"85","author":"S Gallus","year":"2001","unstructured":"Gallus S, Bosetti C, Franceschi S, Levi F, Simonato L, Negri E, et al. Oesophageal cancer in women: tobacco, alcohol, nutritional and hormonal factors. Br J Cancer. 2001;85:341\u20135.","journal-title":"Br J Cancer"},{"key":"1872_CR30","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1097\/CEJ.0b013e32835c7f87","volume":"22","author":"F Islami","year":"2013","unstructured":"Islami F, Cao Y, Kamangar F, Nasrollahzadeh D, Marjani H-A, Shakeri R, et al. Reproductive factors and risk of esophageal squamous cell carcinoma in northern Iran: a case\u2013control study in a high-risk area and literature review. Eur J Cancer Prev. 2013;22:461\u20136.","journal-title":"Eur J Cancer Prev"},{"key":"1872_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/1471-230X-11-49","volume":"11","author":"Z-H Chen","year":"2011","unstructured":"Chen Z-H, Shao J-L, Lin J-R, Zhang X, Chen Q. Reproductive factors and oesophageal cancer in Chinese women: a case-control study. BMC Gastroenterol. 2011;11:49.","journal-title":"BMC Gastroenterol"},{"key":"1872_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-12-566","volume":"12","author":"L Gan","year":"2012","unstructured":"Gan L, He J, Zhang X, Zhang YJ, Yu GZ, Chen Y, et al. Expression profile and prognostic role of sex hormone receptors in gastric cancer. BMC Cancer. 2012;12:566.","journal-title":"BMC Cancer"},{"key":"1872_CR33","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1002\/1097-0142(19900315)65:6<1396::AID-CNCR2820650625>3.0.CO;2-2","volume":"65","author":"CW Wu","year":"1990","unstructured":"Wu CW, Chi CW, Chang TJ, Lui WY, P\u2019Eng FK. Sex hormone receptors in gastric cancer. Cancer. 1990;65:1396\u2013400.","journal-title":"Cancer."},{"key":"1872_CR34","doi-asserted-by":"publisher","first-page":"10584","DOI":"10.18632\/oncotarget.2513","volume":"5","author":"BG Zhang","year":"2014","unstructured":"Zhang BG, Du T, Zang MD, Chang Q, Fan ZY, Li JF, et al. Androgen receptor promotes gastric cancer cell migration and invasion via AKT-phosphorylation dependent upregulation of matrix metalloproteinase 9. Oncotarget. 2014;5:10584\u201395.","journal-title":"Oncotarget."}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-022-01872-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-022-01872-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-022-01872-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T19:09:13Z","timestamp":1661886553000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-022-01872-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,17]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,9,1]]}},"alternative-id":["1872"],"URL":"https:\/\/doi.org\/10.1038\/s41416-022-01872-w","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,17]]},"assertion":[{"value":"1 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Regional Ethical Review Board in Stockholm (reference number 2018\/271-32). The study was performed in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}